Dietary Supplements for Reduction of Intestinal Permeability Levels

N/ANot Yet RecruitingNCT06760377

Universidad Complutense de Madrid85 enrolled

Overview

A randomised and controlled trial, in which the effect of a dietary supplement is evaluated for reduction of intestinal permeability levels of subjects with high levels of zonulin in feces

Randomized clinical trial, with masking of the statistician and the evaluator, to assess the effect of a food supplement, composed of substances that promote intestinal mucosa repair, on the levels of zonulin in feces and consequently on intestinal permeability. A control group of subjects not receiving any type of supplementation will be used to compare the effectiveness of the treatment. The main objective of this study is to determine if the use of a dietary supplement composed of glutamine, butyrate and lion's mane, among others, corrects the levels of zonulin in feces.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

Conditions

Intestinal Permeability Leaky Gut Syndrome Zonulin

Interventions

Dietary supplement GroupDIETARY_SUPPLEMENT

Subjects belonging to the experimental group will be provided with the PermeaIntest supplement, which they will take for 60 days, 1 sachet in the morning and 1 sachet in the evening in half a glass of water. Subjects will have a stool sample collected before and after ingestion of the dietary supplement.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 65 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subjects between 18 and 65 years of age with elevated levels of zonulin in stool (greater than 80 ng/ml). Exclusion Criteria: * Taking any type of antibiotic in the last month * Taking prebiotics or probiotics products in the last month. * Taking laxatives in the last month. * Undergoing any medicinal treatment * Pregnancy * Subject with a history of current gastrointestinal pathology or disorder such as: acute colon pathology, acute haemorrhagic colitis, suspected digestive perforation, recent abdominal surgery, severe arterial hypertension, abdominal hernia, colon neoplasia, history of cardiac syncope, renal failure, liver cirrhosis, epilepsy, severe psychiatric illness (psychosis), necrosis due to abdominal irradiation, severe anaemia, severe neurovegetative lability.

Locations (1)

Universidad Complutense de Madrid

Madrid, Spain

Outcomes

Primary Outcomes

Zonulin levels in feces

Zonulin levels in feces, assessed in ng/ml

Time frame: 60 days

Central Contacts

Isidro Fernández-López Dr. Fernández-López, PT PhD

CONTACT

346255989770 isidrofe@ucm.es

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.